Synonyms: CaCP-29 | IFX-1
Compound class:
Antibody
Comment: Vilobelimab (IFX-1) is a chimeric IgG4 monoclonal antibody against the terminal complement component, anaphylatoxin C5a. It was developed for potential to treat complement mediated inflammatory diseases. Vilobelimab blocks C5a/C5aR1 signalling in subsets of myeloid-derived suppressor cells (MDSCs) and neutrophils.
|
Classification | |
Compound class | Antibody |
International Nonproprietary Names | |
INN number | INN |
11304 | vilobelimab |
Synonyms |
CaCP-29 | IFX-1 |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 1038 |
Other databases | |
GtoPdb PubChem SID | 440816715 |
Search PubMed clinical trials | vilobelimab |
Search PubMed titles | vilobelimab |
Search PubMed titles/abstracts | vilobelimab |